Call Start: 17:00 Call End: 18:01 March 1, 0000 ET
Q1 2025 Earnings Conference Call
May 12, 2025, 05:00 PM ET
Company Participants
Debra Hart - Head, IR
Kevin Herde - EVP and CFO
Trey Martin - CEO
Becky Buzzeo - EVP & CCO
Conference Call Participants
Conor McNamara - RBC Capital Markets
Daniel Arias - Stifel
Tejas Savant - Morgan Stanley
Matthew Stanton - Jeffries
Brandon Coulliard - Wells Fargo
Matthew Hewitt - Craig-Hallum
Operator
Please stand by, we're about to begin. Good afternoon, everyone, and welcome to the Maravai LifeSciences Q1 2025 Results Earnings Call. [Operator Instructions] Also, today's call is being recorded. [Operator Instructions]
At this time, I'll turn things over to Ms. Deb Hart, Head of Investor Relations. Please go ahead, ma'am.
Debra Hart
Good afternoon, everyone. Thanks for joining us for our first quarter 2025 earnings call. Our press release and the slides accompanying today's call are posted on our website and available at investors.maravai.com.
As you can see from our agenda for today on Slide 2, Trey will first provide you with a business update and Kevin will review our financial results and guidance; Becky Buzzeo, our Chief Commercial Officer, will join the call for the question-and-answer session following the prepared remarks.
During today's call, management will make forward-looking statements and refer to GAAP and non-GAAP financial measures. It's possible that actual results could differ from management's expectations. We refer you to Slide 3 for more detail on forward-looking statements and our use of non-GAAP financial measures.
Our just issued press release provides reconciliations to the most directly comparable GAAP measures, and we also post reconciling schedules to the IR website. Please also refer to Maravai's SEC filings for additional information on risks and uncertainties that may impact our operating results, performance, and financial condition.
- Read more current MRVI analysis and news
- View all earnings call transcripts